Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Gemcitabine-cisplatin plus necitumumab vs gemcitabine-cisplatin in first-line stage IV squamous NSCLC
2009-013838-25Phase 3Completed
- Sponsor
- Eli Lilly and Company
- Start
- Sep 2009
- Modality
- Monoclonal Antibodies → Antibody-Based Therapeutics
- Countries
- 1
01
Overview
Phase 3, randomised, open-label trial of necitumumab in Pulmonary squamous cell carcinoma (2 arms), sponsored by Eli Lilly and Company. Primary endpoint: Overall survival. Started Sep 2009; status: completed.
02
Drugs
necitumumab
03
Conditions
Pulmonary squamous cell carcinoma
Beyond the preview
Go deeper on 2009-013838-25.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2009-013838-25.